DOJ Begins Adult-Use Cannabis Rescheduling Hearings — Full 280E Relief Now on the Table
TL;DR: The U.S. Department of Justice has opened formal hearings in late June 2026 to evaluate rescheduling adult-use cannabis from Schedule I, following the landmark April 23 move of medical cannabis to Schedule III. A successful outcome would eliminate 280E taxation entirely for multi-state operators (MSOs), potentially unlocking hundreds of millions in annual cash flow […]
Curaleaf Shareholders Approve Delaware Redomicile, Clearing a Key Hurdle Toward U.S. Exchange Uplisting
TL;DR: Curaleaf Holdings shareholders voted on June 22 to approve the company’s continuation as a Delaware corporation, a structural step that repositions the largest U.S. cannabis multi-state operator for a potential listing on a major American stock exchange. The Delaware redomicile follows months of preparation for an eventual Nasdaq or NYSE uplisting, a move that […]
DEA Judge Finalizes Cannabis Rescheduling Hearing Timeline as MSOS Sector Holds 2026 Highs
TL;DR: A Drug Enforcement Administration administrative law judge formally set the hearing schedule for cannabis rescheduling proceedings today, June 25, signaling that the multi-year regulatory odyssey toward Schedule III classification is entering its most decisive phase. The DEA judge declined to expand the participant list, narrowing the adversarial process to already-qualified parties. Cannabis equities, as […]
Cultivation Consolidation Wave: Which Operators Win?
By Sheeba M. | June 16, 2026 Consolidation Wave: Which Operators Win? TL;DR: Oversupply forces consolidation; winners have efficient cultivation tech and scale. The cannabis cultivation market enters consolidation. Mid-sized growers struggle against operators investing in automation. Megaproducers have scale advantages; craft operators have premium positioning. Reports from Curaleaf and Trulieve show critical metrics. Leaders […]
Cannabis Stocks Rally on FDA Approval Signals
By Sheeba M. | June 16, 2026 Cannabis Stocks Rally on FDA Approval Signals TL;DR: Federal agencies hint at accelerated CBD approvals, unlocking $2B+ for diversified operators. The cannabis sector shows renewed strength this quarter. Recent filings from Curaleaf and Trulieve signal confidence in federal policy evolution. Institutional investors are quietly positioning. DEA comments sparked […]
SAFE Act Delays Push Federal Legalization Timeline to 2027
By Sheeba M. | June 16, 2026 SAFE Act Delays Push Federal Legalization Timeline to 2027 TL;DR: Congressional delays in the SAFE Act schedule suggest federal decriminalization won’t clear a floor vote until Q3 2027, extending state-level cannabis dominance and giving Canadian LPs like Canopy Growth additional time to position for U.S. entry. The timeline […]
State Cannabis Sales Climb to Record $17.5B in 2026 H1
By Sheeba M. | June 16, 2026 State Cannabis Sales Climb to Record $17.5B in 2026 H1 TL;DR: Legal cannabis sales reached $17.5 billion in the first half of 2026 across U.S. markets, signaling sustained consumer demand and potential earnings upside for retail operators like Ayr Wellness and Cresco Labs. The first half of 2026 […]
Why Canadian LPs Are the Play on U.S. Market Normalization
test
Cannabis Sector Shows Recovery Signals as Federal Deadlock Eases
test
Hemp-Derived Delta-9 Market Faces Potential Regulatory Crackdown
By Sheeba M. | June 14, 2026 Hemp-Derived Delta-9 Market Faces Potential Regulatory Crackdown TL;DR: DEA signals stricter enforcement on hemp-derived cannabinoid products, potentially redirecting consumer demand back to licensed dispensaries and benefiting established MSOs. The booming hemp-derived cannabinoid market—which has grown into a multi-billion-dollar gray market largely outside traditional cannabis retail channels—is facing increased […]